Open Access Open Access  Restricted Access Subscription or Fee Access

A survey assessment of clinician perceptions of opioid supply and monitoring requirement policy changes

Amie Goodin, PhD, MPP, Juan M. Hincapie-Castillo, PharmD, MS, PhD, Joshua D. Brown, PharmD, PhD, Dikea Roussos-Ross, MD


Objective: Florida-mandated Prescription Drug Monitoring Program (PDMP) use and restricted Schedule II opioid dispensing for acute pain to 3-day supply in 2018. This study assessed physician perception of these policies.

Design: A cross-sectional study design.

Setting: Large academic medical center.

Patients/participants: Physicians in inpatient and outpatient practice, as stratified by physician specialty for psychiatry or addiction medicine (Psych/AM), primary care, and others.

Interventions: A survey was administered electronically from July to September 2019, with survey items adapted from published opioid policy evaluations.

Main outcome measure: Assessment of physician reason for the use of PDMP and perception of PDMP clinical utility. Responses by specialty were compared via chi square testing.

Results: There were N = 214 responses (response rate ~10.9 percent), representing n = 15 from Psych/AM, n = 58 primary care, and n = 143 from other specialties. The most frequently reported reason for PDMP use across specialties was to examine prescribing history for patients currently using opioid analgesics (6.7 percent Psych/AM; 50.1 percent primary care; 38.6 percent others; p = 0.027). Fewer Psych/AM physicians agreed that the policy hinders the clinical work day as compared with primary care physicians (46.7 percent vs. 58.6 percent). More primary care agreed the policy was a good idea relative to Psych/AM (62.1 percent vs. 53.3 percent). More primary care than Psych/AMs agreed that the policy made it more challenging for chronic pain patients to access opioid therapies (77.6 percent vs. 53.3 percent).

Conclusions: The perceived workflow burden and unintended consequence of decreased chronic pain patient access to opioid pharmacotherapies suggest further opportunities for pharmacist–physician collaboration in managing affected patients.


prescription drug monitoring program, opioids, pharmaceutical policy, clinical workflow

Full Text:



Davis CS, Lieberman AJ, Hernandez-Delgado H, et al.: Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review. Drug Alcohol Depend. 2019; 194: 166-172.

Soelberg CD, Brown Jr RE, Du Vivier D, et al.: The US opioid crisis: Current federal and state legal issues. Anesth Analg. 2017; 125: 1675-1681.

FLA. STAT. § 456.44(1) Controlled Substances Prescribing. 2018.

Hincapie-Castillo JM, Goodin A, Possinger MC, et al.: Changes in opioid use after Florida's restriction law for acute pain prescriptions. JAMA Netw Open. 2020; 3: e200234.

Kelley K, Clark B, Brown V, et al.: Good practice in the conduct and reporting of survey research. Int J Qual Health Care. 2003; 15: 261-266.

Goodin AJ, Brown JD, Delcher C, et al.: Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Res Social Adm Pharm. 2020; 16(9): 1306-1308.

Delcher C, Wang Y, Young HW, 2nd, et al.: Trends in Florida's prescription drug monitoring program registration and utilization: Implications for increasing voluntary use. J Opioid Manag. 2017; 13: 283-289.

Freeman PR, Goodin A, Troske S, et al.: Kentucky House Bill 1 Impact Evaluation. Lexington, KY: Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, 2015.

Sun BC, Lupulescu-Mann N, Charlesworth CJ, et al.: Variations in prescription drug monitoring program use by prescriber specialty. J Subst Abuse Treat. 2018; 94: 35-40.

Blum CJ, Nelson LS, Hoffman RS: A survey of physicians’ perspectives on the new York State Mandatory Prescription Monitoring Program (ISTOP). J Subst Abuse Treat. 2016; 70: 35-43.

Curran GM, Freeman PR, Martin BC, et al.: Communication between pharmacists and primary care physicians in the midst of a US opioid crisis. Res Social Adm Pharm. 2019; 15: 974-985.

Delcher C, Wang Y, Goodin A, et al.: Rapid expansion of the opioid ecosystem: National implications for prescriber-pharmacist communication. Am J Prev Med. 2018; 55: 656-661.

Dykema J, Jones NR, Piche T, et al.: Surveying clinicians by web: Current issues in design and administration. Eval Health Prof. 2013; 36: 352-381.

Brtnikova M, Crane LA, Allison MA, et al.: A method for achieving high response rates in national surveys of US primary care physicians. PLoS One. 2018; 13(8): 1-13.

Burns KE, Duffett M, Kho ME, et al.: A guide for the design and conduct of self-administered surveys of clinicians. CMAJ. 2008; 179: 245-252.

Brtnikova M, Crane LA, Allison MA, et al.: A method for achieving high response rates in national surveys of US primary care physicians. PLoS One. 2018; 13: e0202755.



  • There are currently no refbacks.